Availability and buying

when will retatrutide be available

Published May 2, 2026Updated May 3, 2026Medical safety, official-source, and research-reference review

There is no guaranteed public availability date. Availability depends on trial completion, regulatory submission, review, and approval.

Direct answer

Lilly says retatrutide is in clinical development and public launch depends on completing trials and the regulatory approval process. As of May 2, 2026, it is not FDA approved or publicly available.

Research context

These references frame the evidence base behind this topic. They are not medical advice, approval, or instructions for using retatrutide outside a clinical trial.

Short source quoteagonist of the GIP, GLP-1, and glucagon receptors

Jastreboff et al., NEJM 2023 retatrutide phase 2 obesity trial

This peer-reviewed phase 2 paper is the anchor for retatrutide mechanism language. It does not make retatrutide approved or publicly available.

Short source quoterandomised, double-blind, placebo and active-controlled

Rosenstock et al., Lancet 2023 retatrutide phase 2 type 2 diabetes trial

The type 2 diabetes phase 2 paper helps separate controlled clinical research from online self-use claims.

Short source quotequality of the prescription drugs sold online

Lim et al., 2022 systematic review of online pharmacies selling prescription drugs

This systematic review supports online-source caution for prescription-drug searches and marketplace claims.

Short source quoteselling counterfeit, adulterated or unapproved drugs

Limbu and Huhmann, 2023 scoping review of illicit online pharmacies

This scoping review supports warnings about illicit online pharmacies and unapproved prescription-drug access.

Short source quotepreparation errors

McCall et al., Expert Opinion on Drug Safety 2026 compounded GLP-1 pharmacovigilance study

This pharmacovigilance study is relevant to compounded GLP-1 safety signals and product-quality concerns.

What to know before acting on this search

Lilly's March 2026 FAQ says additional results from the clinical trial program are expected over the next year.
Lilly has announced positive topline results from some Phase 3 studies, but topline results are not the same as FDA approval.
Regulatory review can change timelines, labels, indications, and availability.

Safety and compliance notes

Any website promising public access before approval should be read skeptically.
A future approval, if it happens, may apply only to specific indications and populations.
Patients should not bridge the wait with unapproved research-use products.

Safer next step

Monitor the FDA status and clinical-trials pages instead of relying on seller availability claims.

Medical disclaimer

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. I am not a medical professional. Always consult a qualified healthcare provider before starting, stopping, or changing any weight loss treatment. Individual results vary. Retatrutide is investigational and is not FDA approved. FDA-approved options such as semaglutide and tirzepatide require prescriptions and should only be used under medical supervision.